An interventional study of stellate ganglion block with 0.5% ropivacaine in Stellate Ganglion Block, Prolonged Disorders of Consciousness and Sleep, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Consciousness Disorders with a site in China — 30 open to participants now, 31 under way, 1 of them phase 3. Consciousness Disorders · China.
Among the 70 studies in Consciousness Disorders with a site in China, this one is the 35th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 24 of the 30 other live ones, and was the 65th registered.
291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.
Browse Consciousness Disorders studies →30 of the 70 studies in Consciousness Disorders with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Xijing Hospital · Sites in China
Ages 18–80
Zhujiang Hospital · Sites in China
Ages 18–70
Guangzhou General Hospital of Guangzhou Military Command · Sites in China
Ages 3–65
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 47 across 192 interventional studies indexed under Consciousness Disorders.
Median enrollment 60 across the 40 interventional studies, 120 across the 30 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 70 have an industry lead sponsor. The 10 most frequent:
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
Beijing Tiantan Hospital has 7 studies filed under Consciousness Disorders — fewer than ten, so there is no comparison to draw.
8 of the studies in Consciousness Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06406413First Affiliated Hospital of Zhejiang UniversityMicro-movements in Patients With Prolonged Disorders of Consciousness | 2026-12 |
| NCT06088628First Affiliated Hospital of Zhejiang UniversityMicro-expressions in Patients With Prolonged Disorders of Consciousness | 2026-12 |
| NCT06268236The Second Affiliated Hospital, Guangzhou University of Traditional Chinese MedicineElectro-acupuncture to Treat Disorder of Consciousness | 2026-12-31 |
| NCT07183670Hongying Jiang, MDA Speaking-Valve-Based Decannulation Protoco for Patients With a Prolonged Disorders of Consciousness | 2027-02-01 |
| NCT07173634Hongying Jiang, MDSpeaking Valve Trial vs. Capping Trial for Tracheostomy Decannulation in Prolonged Disorders of Consciousness | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 70 studies in Consciousness Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-centre, single-arm, self-controlled, exploratory pilot study.
The goal of this clinical trial is to learn about the effect of preoperative administration of stellate ganglion block on postoperative sleep status in patients with prolonged disorders of consciousness. The main aims to answer are: To explore the feasibility and safety of unilateral SGB in pDOC patients, evaluate its impact on sleep time and sleep architecture from the preoperative night to the night of surgery, compare the cerebral hemodynamic parameters, cerebral oxygen saturation and Coma Recovery Scale-Revised (CRS-R) scores in pDOC patients before and after SGB, and inform the design and sample size calculation of a future definitive RCT.
Participants will be pDoC patients with intact skulls after acquired brain injury who will undergo spinal cord electronic stimulator implantation under general anesthesia at Beijing Tiantan Hospital. Stellate ganglion block will be administrated before the surgery. Polysomnography, total sleep time, cerebral oxygen saturation, cerebral hemodynamic parameters, CRS-R scores will be investigated.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
preoperative administration of stellate ganglion block
Drug: stellate ganglion block with 0.5% ropivacaine
A single dose of ultrasound-guided stellate ganglion block with 0.5% ropivacaine was administered to the pDoC patients after induction of general anesthesia but before surgical incision.
The change in total sleep time
total sleep time on PSG
Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
sleep structure before and after SGB
sleep structure will be measured using polysomnography (PSG)
Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
sleep latencies before and after SGB
sleep latencies will be measured using polysomnography (PSG)
Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
sleep stage distribution before and after SGB
sleep stage distribution will be measured using polysomnography (PSG)
Time frame: from the baseline night (the night before surgery) to the night of surgery (postoperative night 1)
Change in cerebral oxygen saturation
Regional cerebral oxygen saturation (rSO₂) measured by near-infrared spectroscopy (NIRS).
Time frame: 30 minutes after stellate ganglion block
Change in cerebral hemodynamic parameters
cerebral hemodynamic parameters measured by Transcranial Doppler(TCD)
Time frame: 30 minutes after stellate ganglion block.
the recovery of consciousness
Consciousness recovery will be assessed using the Coma Recovery Scale-Revised (CRS-R). It assesses patients across six functional domains: auditory, visual, motor, oromotor/verbal, communication, and arousal. The total score ranges from 0 to 23, with higher scores indicating a higher level of consciousness.
Time frame: 1 and 30 days postoperatively
Length of ICU stay
Time frame: 30 days postoperatively
Costs of ICU stay
Time frame: 30 days postoperatively
Safety outcomes
SGB-related complications and unanticipated adverse events
Time frame: 30 days postoperatively
Feasibility outcomes
Time frame: 30 days postoperatively
SGB success rate
Time frame: 30 days postoperatively
PSG data completeness
Time frame: 30 days postoperatively
adverse event rate
Time frame: 30 days postoperatively
Plan to share: Yes — All data generated or analysed during this study will be included in published article. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Access criteria: The data that support the findings of this study are available from the corresponding author upon reasonable request.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.
Of 90 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 9 months is below that.
Counting every sponsor, half of 95 studies reached it within 19 months; a quarter within 8 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jan 2026 → Oct 2026, primary completion Jul 2026 → Jul 2027 and completion Jan 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.